These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 23621168)

  • 1. Obesity and outcomes in patients treated with chemoradiotherapy for esophageal carcinoma.
    Wang J; Myles B; Wei C; Chang JY; Hofstetter WL; Ajani JA; Swisher SG; Cox JD; Komaki R; Liao Z; Lin SH
    Dis Esophagus; 2014; 27(2):168-75. PubMed ID: 23621168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
    Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
    Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trimodality therapy of esophagectomy plus neoadjuvant chemoradiotherapy improves the survival of clinical stage II/III esophageal squamous cell carcinoma patients.
    Fujiwara Y; Yoshikawa R; Kamikonya N; Nakayama T; Kitani K; Tsujie M; Yukawa M; Inoue M; Yamamura T
    Oncol Rep; 2012 Aug; 28(2):446-52. PubMed ID: 22664791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
    Swisher SG; Maish M; Erasmus JJ; Correa AM; Ajani JA; Bresalier R; Komaki R; Macapinlac H; Munden RF; Putnam JB; Rice D; Smythe WR; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
    Ann Thorac Surg; 2004 Oct; 78(4):1152-60; discussion 1152-60. PubMed ID: 15464463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT
    Tang H; Tan L; Shen Y; Wang H; Lin M; Feng M; Xu S; Guo W; Qian C; Liu T; Zeng Z; Hou Y; Yu Z; Jiang H; Li Z; Chen C; Lian C; Du M; Li H; Xie D; Yin J; Zhao N; Wang Q
    BMC Cancer; 2017 Jun; 17(1):450. PubMed ID: 28659128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Body mass index and survival in esophageal adenocarcinoma treated with chemoradiotherapy followed by esophagectomy.
    Shridhar R; Hayman T; Hoffe SE; Weber J; Almhanna K; Chuong M; Karl RC; Meredith KL
    J Gastrointest Surg; 2012 Jul; 16(7):1296-302. PubMed ID: 22399271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant versus definitive chemoradiotherapy for locally advanced esophageal cancer : Outcomes and patterns of failure.
    Haefner MF; Lang K; Verma V; Koerber SA; Uhlmann L; Debus J; Sterzing F
    Strahlenther Onkol; 2018 Feb; 194(2):116-124. PubMed ID: 28916906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcomes following neoadjuvant chemoradiotherapy in patients with clinical T2N0 esophageal squamous cell carcinoma.
    Chen WH; Chao YK; Chang HK; Tseng CK; Wu YC; Liu YH; Hsieh MJ; Liu HP
    Dis Esophagus; 2012 Apr; 25(3):250-5. PubMed ID: 21951719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison between surgery and definitive chemoradiotherapy for patients with resectable esophageal squamous cell carcinoma: a propensity score analysis.
    Nomura M; Oze I; Kodaira T; Abe T; Komori A; Narita Y; Masuishi T; Taniguchi H; Kadowaki S; Ura T; Andoh M; Tachibana H; Uemura N; Tajika M; Niwa Y; Muto M; Muro K
    Int J Clin Oncol; 2016 Oct; 21(5):890-898. PubMed ID: 26980212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer.
    Chang KJ; Reid T; Senzer N; Swisher S; Pinto H; Hanna N; Chak A; Soetikno R
    Gastrointest Endosc; 2012 Jun; 75(6):1139-46.e2. PubMed ID: 22520270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Esophageal cancer: outcome according to therapeutic strategy].
    Rousseau D; Capitain O; Denis F; Girault S; Poirier AL; Paumier A; Cellier P; Hamy A; Mahé MA; Mesgouez-Nebout N
    Cancer Radiother; 2013 Feb; 17(1):10-20. PubMed ID: 23270680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphorylated mammalian target of rapamycin expression is associated with the response to chemoradiotherapy in patients with esophageal squamous cell carcinoma.
    Li SH; Huang EY; Lu HI; Huang WT; Yen CC; Huang WC; Chen CH
    J Thorac Cardiovasc Surg; 2012 Dec; 144(6):1352-9, 1359.e1. PubMed ID: 22841170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-institution retrospective comparison of preoperative versus definitive chemoradiotherapy for adenocarcinoma of the esophagus.
    Shridhar R; Freilich J; Hoffe SE; Almhanna K; Fulp WJ; Yue B; Karl RC; Meredith K
    Ann Surg Oncol; 2014 Nov; 21(12):3744-50. PubMed ID: 24854492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiation field size and dose determine oncologic outcome in esophageal cancer.
    Gemici C; Yaprak G; Batirel HF; Ilhan M; Mayadagli A
    World J Surg Oncol; 2016 Oct; 14(1):263. PubMed ID: 27737673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective review of patients with locally advanced esophageal cancer treated at the University of Pittsburgh.
    Defoe SG; Pennathur A; Flickinger JC; Heron DE; Gibson MK; Luketich JD; Greenberger JS
    Am J Clin Oncol; 2011 Dec; 34(6):587-92. PubMed ID: 22101387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
    Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
    Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can metformin improve 'the tomorrow' of patients treated for oesophageal cancer?
    Van De Voorde L; Janssen L; Larue R; Houben R; Buijsen J; Sosef M; Vanneste B; Schraepen MC; Berbée M; Lambin P
    Eur J Surg Oncol; 2015 Oct; 41(10):1333-9. PubMed ID: 26091848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different recurrence pattern after neoadjuvant chemoradiotherapy compared to surgery alone in esophageal cancer patients.
    Smit JK; Güler S; Beukema JC; Mul VE; Burgerhof JG; Hospers GA; Plukker JT
    Ann Surg Oncol; 2013 Nov; 20(12):4008-15. PubMed ID: 23838922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A high body mass index in esophageal cancer patients is not associated with adverse outcomes following esophagectomy.
    Miao L; Chen H; Xiang J; Zhang Y
    J Cancer Res Clin Oncol; 2015 May; 141(5):941-50. PubMed ID: 25428458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of weekly docetaxel combined with preoperative radiotherapy for locally advanced esophageal cancer from pathological analysis.
    Kushida T; Nohara S; Yoshino K; Fujiwara D; Ouchi K; Amano T; Isayama F; Tomita N; Iwanuma Y; Sasai K; Tsurumaru M; Kajiyama Y
    Dis Esophagus; 2014; 27(4):368-73. PubMed ID: 23865505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.